LOS ANGELES, March 25 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that it has been and continues to ship orders under what Dr. Harmison calls an “efficient production line at its manufacturing facility.” Additionally, the Company has received an additional $7.5 million in Fidelity 100 device delivery orders in the month of March, 2008, which the company intends to fill during the next two quarters. The Company said it may fill these orders sooner.
Dr. Harmison stated: “I am very comfortable with our production line capabilities in terms of their immediate capacity - which will now ramp up to a minimum of 125 production model Fidelity 100 devices per month and grow from there. This capability will be expanded significantly to meet growing demand.
The Company also added that it is continuing discussions with its European and Asian partners (and prospective ones), and Dr. Harmison “anticipates that these opportunities will bear fruit ten days from today. I am pleased to be able to provide this update.”
In finishing, Dr. Harmison stated: “The reach of the Frost & Sullivan organization into Asia -and our devices having won the Frost technology awards in two out of three years - has been a significant marketing tool whose uses are obvious and are compelling.”
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.
The Company has moved its corporate headquarters back to Los Angeles, California following the termination of prior management who desired the Greenville, South Carolina location and based their prospective success on that location - which never came to fruition. The Company continues to consult with several employees and professionals in the Greenville area.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the Signalife devices, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
CONTACT: Dr. Lowell T. Harmison, CEO, Signalife, Inc., +1-864-233-2300
Web site: http://www.signalife.com/
